Sophiris, Stock Sliding After Cancer Drug Data, Still Plans Phase 3

Sophiris Bio said Monday that 10 patients who were administered its experimental prostate cancer drug a second time didn?t see any additional benefit. The news sent the San Diego, CA, and Vancouver, BC-based biotech?s stock plunging about 40 percent. Sophiris (NASDAQ: SPHS) already had encouraging mid-stage clinical trial data testing one dose of its drug, [?]